focus -WSS

focus

author：focus 2025-09-03 07:44:37 - browse：8

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： With psoriasis trial ahead, Alumis raises $259 million

WSS

Snowpack in the West is melting rapidly. Where will all that extra water go?

Change Healthcare cyberattack prompts Medicare loan program

HCA says smaller share of spending going to labor

The drug industry has found itself all alone in Washington

Air quality improving but still lags in Black, Hispanic communities

With psoriasis trial ahead, Alumis raises $259 million

focus

focus

focus

Jerome Adams on the need for new antivirals for Covid

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Medical leaders decry Supreme Court decision on affirmative action

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Continuity nursing helped my family in our darkest PICU moments

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Drug repurposing or repositioning? The language matters

A deep dive into Applied Therapeutics’ data, and questions on Cassava

explore

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Amylyx ALS drug failure raises questions and concerns

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

The drug industry has found itself all alone in Washington

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

leisure time

hotspot

Wikipedia

hotspot